[Form 3] DEXCOM INC Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Dexcom Inc. director Albert Frederick Osterloh IV has filed an initial Form 3, which is the baseline statement of his ownership in the company’s securities as an insider. The filing reports no transactions, meaning there are no recent insider share purchases, sales, or other dealings disclosed in this document.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Osterloh Albert Frederick IV

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/26/2026

3. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Albert Frederick Osterloh IV	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Dexcom (DXCM) Form 3 filing for Albert Frederick Osterloh IV show?

The Form 3 shows that Albert Frederick Osterloh IV is a director of Dexcom Inc.. It serves as his initial ownership statement as an insider, and this filing reports no associated stock transactions or changes in holdings.

Does the Dexcom (DXCM) Form 3 report any insider buying or selling?

No, the Form 3 for Dexcom director Albert Frederick Osterloh IV reports no transactions. The transaction summary shows zero buys, zero sells, and no other types of trades linked to this initial ownership filing.

Who is the reporting person in Dexcom’s (DXCM) latest Form 3 filing?

The reporting person is Albert Frederick Osterloh IV, identified as a director of Dexcom Inc. The filing confirms his insider status but does not list any stock purchases, sales, or other security transactions.

Does the Dexcom (DXCM) Form 3 indicate that the director is a 10% owner?

No, the Form 3 indicates that Albert Frederick Osterloh IV is not a ten percent owner. He is reported solely in his role as a director, with no additional status as a large beneficial shareholder in this filing.

What is summarized in the transaction section of Dexcom’s (DXCM) Form 3?

The transaction summary shows no activity: zero buys, zero sells, and no other transaction types. This confirms the document is an initial ownership statement without any contemporaneous trading in Dexcom securities by the reporting director.